losartan has been researched along with Corneal Diseases in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Corneal Diseases: Diseases of the cornea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to examine the effect of topical and/or oral angiotensin converting enzyme II inhibitor and TGF-beta signaling blocker losartan on corneal stromal fibrosis that developed in rabbit corneas after Descemetorhexis removal of central Descemet's membrane and corneal endothelium." | 8.12 | Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits. ( Hilgert, GSL; Murillo, SE; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022) |
| "To evaluate the efficacy of losartan and prednisolone acetate in inhibiting corneal scarring fibrosis after alkali burn injury in rabbits." | 8.12 | Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury. ( Hilgert, GSL; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022) |
| "Losartan is an inhibitor of transforming growth factor-β signaling." | 5.72 | Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience. ( Ambrósio, R; Bandeira, F; Pereira-Souza, AL; Salomão, MQ; Souza Lima, A; Wilson, SE, 2022) |
| "The purpose of this study was to examine the effect of topical and/or oral angiotensin converting enzyme II inhibitor and TGF-beta signaling blocker losartan on corneal stromal fibrosis that developed in rabbit corneas after Descemetorhexis removal of central Descemet's membrane and corneal endothelium." | 4.12 | Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits. ( Hilgert, GSL; Murillo, SE; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022) |
| "To evaluate the efficacy of losartan and prednisolone acetate in inhibiting corneal scarring fibrosis after alkali burn injury in rabbits." | 4.12 | Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury. ( Hilgert, GSL; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022) |
| "Losartan is an inhibitor of transforming growth factor-β signaling." | 1.72 | Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience. ( Ambrósio, R; Bandeira, F; Pereira-Souza, AL; Salomão, MQ; Souza Lima, A; Wilson, SE, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sampaio, LP | 2 |
| Hilgert, GSL | 2 |
| Shiju, TM | 2 |
| Murillo, SE | 1 |
| Santhiago, MR | 2 |
| Wilson, SE | 3 |
| Pereira-Souza, AL | 1 |
| Ambrósio, R | 1 |
| Bandeira, F | 1 |
| Salomão, MQ | 1 |
| Souza Lima, A | 1 |
3 other studies available for losartan and Corneal Diseases
| Article | Year |
|---|---|
Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits.
Topics: Actins; Administration, Ophthalmic; Angiotensin II Type 1 Receptor Blockers; Animals; Cicatrix; Coll | 2022 |
Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury.
Topics: Adrenal Cortex Hormones; Alkalies; Animals; Burns, Chemical; Cicatrix; Collagen Type IV; Corneal Dis | 2022 |
Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience.
Topics: Adult; Corneal Diseases; Corneal Opacity; Corneal Stroma; Female; Fibrosis; Humans; Keratomileusis, | 2022 |